Back to search

University of Thessaly (UTH)

Ανίχνευση μεταλλάξεων των γονιδίων NPM1 και FLT3 σε ασθενείς με οξεία μυελογενή λευχαιμία και MDS: high IPSS, int-2 κατά WHO

Abstract

dc:description

Purpose: NPM1 and FLT3-mutations have a prognostic significance in patients with AML. Studies show that their co-existance can highlight subpopulations with different prognosis, important for their therapy approach and survival. The purpose of this study was to determine the incidence of the mutations in Greek patients with AML, CMML and RAEB and to detect correlations with other clinical and laboratory characteristics.Materials and methods: DNA was extracted from 140 patients – 109 with de novo and secondary AML, 12 with RAEB I, 10 with RAEB II and 9 patients with CMML. The FLT3-ITD length mutation was estimated by PCR, the point-mutation of FLT3 by PCR-RFLP and the NPM1-mutations by Fragment-analysis. We searched associations with clinical characteristics, laboratory and immunohistochemical findings and karyotype. Results: In Greek patients with AML, the incidence of the FLT3-ITD, FLT3-TKD and NPM1-mutations was 11.9%, 6.4% and 17.4% respectively. FLT3-ITD-positive patients had a more aggressive leukaemia, with higher leucocytes (p<0.001). WBC numbers higher than 60000/mm3, predicted the presence of the mutation with 90% specificity. The same patients had higher LDH-values (p=0.006). A normal LDH, excluded the mutation with 95% sencitivity. The patients were 7 times more likely to be NPM1-mutated too and their blasts had lower (<50%) expression of CD34 (p=0.008). FLT3-TKD-positive patients had often lymphadenopathy (p=0.026) and their blasts expressed CD14 (p<0.001). NPM1-mutated patients usually had de novo leukaemia (p=0.039), and higher LDH-values (p<0.001). A normal LDH, practically excluded the presence of the mutation with a 100% sencitivity. Immunohistochemically the blasts had a lower expression of CD34 (p<0.001), CD13 (p=0.009) and CD117 (p=0.003), absence of HLA-DR (p=0.038) and a higher expression of CD116 (p for linear trend<0.001), CD15 (p=0.014) and CD36 (p=0.007). The patients were 8 times more likely to carry the FLT3-ITD, but no correlation was made with the point mutation of the receptor. The incidence of the 3 mutations in MDS/MPN patients was 6.4% each.Conclusions: Greek patients with AML carry the FLT3-mutation with half the frequency compared to the literature, but the same biological characteristics. This is the same with the Nucleophosmin-mutations. The 2 mutated genes often co-exist and combine the biological characteristics of the diseases, making it necessary to always search them both in a Greek patient too. In our analysis, we saw that simple and low cost exams (WBC and LDH) can be very important for prognosis and could help the Clinical Hematologist choose the patients who are more likely to carry the mutations, lowering the cost of risk stratification. In our 31 RAEB and CMML-patients, the incidence of the three mutations is two to ten times higher than the literature, which makes greek patients with myelodysplastic syndromes ideal to research the mutations.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Befani, Maria
  • Μπεφάνη, Μαρία

Subjects

dc:subject × 7

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/37352

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Befani, Maria; Μπεφάνη, Μαρία. Ανίχνευση μεταλλάξεων των γονιδίων NPM1 και FLT3 σε ασθενείς με οξεία μυελογενή λευχαιμία και MDS: high IPSS, int-2 κατά WHO. University of Thessaly (UTH), 2016. http://hdl.handle.net/10442/hedi/37352